AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04223193 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matching to tavapadon QD orally for 27 weeks.
Study NCT04615273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lonapegsomatropin
Description: Due to the different human growth hormone (hGH) dose requirements, depending on participant's age and concomitant use of oral estrogen, this trial has 3 dosing groups per arm, followed by gradual increasing dose titration to a target maintenance dose.
Study NCT04615273 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo for lonapegsomatropin drug product contained the same excipients as lonapegsomatropin drug product but does not contain lonapegsomatropin itself. The placebo solution was administered by subcutaneous (SC) injection via syringe and needle. Due to the different hGH dose requirements, depending on participant's age and concomitant use of oral estrogen, this trial has 3 dosing groups and the placebo received the same dose volume as if they were randomized to once-weekly lonapegsomatropin.
Study NCT04615273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Somatropin
Description: Somatropin solution is provided in a pre-filled pen intended for daily subcutaneous injection. Due to the different hGH dose requirements, depending on participant's age and concomitant use of oral estrogen, this trial has 3 dosing groups per arm, followed by gradual increasing dose titration to a target maintenance dose.
Study NCT02779257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide
Description: Pasireotide will be used, in addition to diazoxide, as a medical treatment to blunt hypoglycemia in the setting of autonomous insulin secretion.
Study NCT02779257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazoxide
Description: Pasireotide will be used, in addition to diazoxide, as a medical treatment to blunt hypoglycemia in the setting of autonomous insulin secretion.
Study NCT00857025 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Assessment pre-study and week 5, week 9, week 13 and at off study.
Study NCT02221206 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mini-Screw implant
Description: Mini-screw implants (VectorTASTM8\*1.4mm, Ormco Corporation, USA) were placed between maxillary first molar and second molar after local anesthetic on both sides
Study NCT00435370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tropisetron
Description: 10 mg/day
Study NCT00435370 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT00435370 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Risperidone
Description: 6mg/day
Study NCT03946215 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Each participant will perform:
Description: Part 1: Maximal incremental tests will require running at fixed slopes (+15%, 0% -15%) for stages (2min duration) of increasing velocities (0.5, 1 and 1.5 km/h) Part two: submaximal running tests will require running at constant velocity (80% VO2max uphill; 80%VO2max downhill and downhill at similar velocity as uphill)
Study NCT02360657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911, 10 mg
Description: JNJ-54861911, 10 mg (2\*5 mg tablet) orally once daily for 4 weeks.
Study NCT02360657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911, 50 mg
Description: JNJ-54861911, 50 mg (2\*25 mg tablet) orally once daily for 4 weeks.
Study NCT00435370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: 6mg/day
Study NCT01311102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: 1.33 cc 2% liquid lidocaine
Study NCT01311102 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 1.33cc normal saline
Study NCT00158743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-digoxin antibody (FAB fragment)
Description: intravenous administered, dose based on weight (assuming 4ng/mL EDLF concentration). Dose every 6 hours x 48 hours.
Study NCT00158743 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sodium chloride
Study NCT03701724 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Systematic maintenance rTMS
Description: Same parameters as the initial course (session of 8,5 minutes, at 1 Hz, on the right dorsolateral prefrontal cortex (DLPFC) targeting with either neuronavigation or the Beam). The frequency is : 2 sessions / week during 1 month, then 1 session / week during 2 months and finally 1 session every 2 weeks during 8 months.
Study NCT03701724 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS course in case of relapse
Description: Same parameters as the initial course. The frequency is the same as the initial course: one daily session on 5 consecutive working days from Monday to Friday for at least 20 to 30 sessions over 4 to 6 weeks.
Study NCT02360657 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to JNJ-54861911 tablet orally once daily for 4 weeks.
Study NCT01098240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-601,927
Description: CP-601,927 1-2 mg twice per day, oral 1 mg tablets, for 6 weeks.
Study NCT03701724 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham rTMS
Description: The sham stimulation consists of the identical rTMS procedure at the identical location using a commercial figure-eight sham coil. However, it does not produce the identical tactile sensation. A local electrical stimulation will be delivered with two disposable Electromyogram (EMG) electrodes using a transcutaneous electrical nerve stimulation (TENS) Stimulator.
Study NCT02612402 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: messages generated by learning algorithm
Description: THIS INTERVENTION HAS BEEN INCLUDED IN THE LEARNING ALGORITHM ARM The app measures physical activity by the phone accelerometer and sends SMS messages to encourage activity. An automatic learning algorithm for encouraging physical activity learns the patterns of response for each patient and chooses the best messages for the patient to encourage activity.
Study NCT02612402 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: constant weekly message reminding patient to exercise
Description: THIS INTERVENTION HAS BEEN INCLUDED IN THE CONTROL ARM The app measures physical activity by the phone accelerometer and sends a constant SMS messages to remind the patient to exercise.
Study NCT00851214 — intervention group
Intervention type: DEVICE
Intervention: NexfinHD Monitor
Description: Finger cuff device (NexfinHD Monitor, BMEYE, Amsterdam) that can measure hemodynamics on a beat to beat basis and that can be easily applied to acutely ill individuals.
Study NCT03024073 — intervention group
Intervention type: PROCEDURE
Intervention: BB-Phaco
Description: Phacoemulsification with bilateral bifocal lenses implantation
Study NCT03034577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Reversal of neuromuscular block Sugammadex dosage will be adjusted to body weight and PTC/TOF count at the time of reversal, and not administered until PTC at least 1. Dosage will be 4mg/kg if TOF = 0 and PTC ≥ 1; and 2 mg/kg if TOF ≥1.
Study NCT01098240 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets, taken orally, twice per day, for 6 weeks.
Study NCT00251628 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: standard care
Study NCT00251628 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ATC Dosing
Description: ATC dosing of a weight-appropriate dose of a nonopioid/opioid combination analgesic, every 4 hours around-the-clock for the first 3 days following surgery
Study NCT00251628 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ATC Dosing
Description: ATC dosing of a weight-appropriate dose of a nonopioid/opioid combination analgesic, every 4 hours around-the-clock for the first 3 days following surgery
Study NCT00251628 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured Pain Management Program
Description: The structured pain management program consisted of a nurse coaching intervention which included an evaluation of the child's current condition, review of the pain intensity scores, verification that the child was taking the pain medication, re-education regarding the rationale for ATC dosing, review of strategies to facilitate medication administration, and re-education about potential side effects associated with analgesic administration.
Study NCT00251628 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: As needed dosing
Description: As needed analgesic dosing with a weight-appropriate dose of a nonopioid/opioid combination analgesic, every 4 hours as needed for pain.
Study NCT00544557 — intervention group
Intervention type: DRUG
Intervention: Etanercept
Description: The patients will be treated in accordance with the requirements of the labeling of etanercept in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
Study NCT02926378 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture Treatments
Description: Every participant will receive six acupuncture treatments across a three to four-week period. The treatments will last a total of about one hour, including a 10 minute initial assessment, needling, and 45 min of lying down with the needles. Two treatments a week will be performed by Dr. Siminovich-Blok, the PI of this study and a NYS licensed acupuncturist at NYU Langone Medical Center (NYULMC) Ambulatory Care Center. Each acupuncture treatment will consist of 1) a combination of a fixed set of points suggested by the literature, and 2) an individualized set of points based on the evaluation by the licensed acupuncturist. The first set of points will consist of 4 acupoints used consistently in the treatment of stroke through the literature.
Study NCT01127191 — intervention group
Intervention type: OTHER
Intervention: military equipment
Description: Military exercise of 24 hours
Study NCT03476447 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: B. infantis EVC001
Description: A once-daily oral feeding of B. infantis EVC001 will be mixed with breast milk and provided to infants for 28 consecutive days.
Study NCT03476447 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lactose
Description: A once-daily oral feeding of a lactose placebo will be mixed with breast milk and provided to infants for 28 consecutive days.
Study NCT02266706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftolozane/Tazobactam 1000/500 mg
Description: A fixed dose combination (FDC) of 1000 mg ceftolozane and 500 mg tazobactam as a 60 minute infusion.
Study NCT02266706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftolozane/Tazobactam 30/15 mg/kg
Description: A FDC of 30 mg/kg of ceftolozane and 15 mg/kg of tazobactam as a 60 minute infusion.
Study NCT02266706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftolozane/Tazobactam 20/10 mg/kg
Description: A FDC of 20 mg/kg of ceftolozane and 10 mg/kg of tazobactam as a 60 minute infusion.
Study NCT02266706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftolozane/Tazobactam 18/9 mg/kg
Description: A FDC of 18 mg/kg of ceftolozane and 9 mg/kg of tazobactam as a 60 minute infusion.
Study NCT02266706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftolozane/Tazobactam 12/6 mg/kg
Description: A FDC of 12 mg/kg of ceftolozane and 6 mg/kg of tazobactam as a 60 minute infusion.
Study NCT02309632 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pancreatic Cancer Screening Pathway 1
Description: Screening with imaging and biomarker testing
Study NCT02309632 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pancreatic Cancer Screening Pathway 2
Description: Screening with biomarker testing only
Study NCT02086656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine, oxaliplatin, irinotecan and bevacizumab
Description: perioperative COI-B
Study NCT01260428 — intervention group
Intervention type: DEVICE
Intervention: threshold PEEP
Description: Various set of pressures : 0, 5, 10 cm H20; pursed lips breathing
Study NCT02169583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1325756 Solution
Description: Solution containing 2 mg/mL GSK1325756 in sterile water for injection, to be administered intravenously.
Study NCT02169583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1325756 Solution Matching Placebo
Description: Solution containing sterile water for injection matching GSK1325756 solution, to be administered intravenously.
Study NCT02169583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1325756 Tablet
Description: A white film coated tablet containing 50 mg GSK1325756 to be administered orally.
Study NCT02169583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1325756 Tablet Matching Placebo
Description: A white film coated tablet matching GSK1325756 tablet, to be administered orally.
Study NCT03675191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orlistat 120Mg Cap
Description: Drug,Orlistat 120Mg Cap, three times a day, within 1hour after meal
Study NCT03675191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine Pill
Description: Drug,Phentermine Pill 37.5mg, both in two arms, one time a day, within 1hour after meal
Study NCT03675191 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Phentermine Pill
Description: Drug,Phentermine Pill 37.5mg, both in two arms, one time a day, within 1hour after meal
Study NCT01188928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcipotriol plus betamethasone
Description: Topical suspension once daily for up to 8 weeks.
Study NCT01188928 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone-17,21-dipropionate
Description: Topical suspension once daily for up to 8 weeks.
Study NCT01188928 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcipotriene
Description: Topical suspension once daily for up to 8 weeks.
Study NCT01188928 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical suspension vehicle
Description: Topical suspension once daily for up to 8 weeks.
Study NCT00063960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: floxuridine
Study NCT00063960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study NCT01333176 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Point-of-care finger-poke HbA1c determination.
Description: All volunteers receive finger-poke HbA1c test. Result: If \< 6: Offered a requisition to have gold standard testing for diabetes screening. If 6-6.5: Given requisition for FBG, HbA1c and OGTT. If A1c result >6.5: Counseled that they may have diabetes. Given requisition as above.~Estimates about how many have undiagnosed diabetes will be calculated.~1. Did the clients who were counseled to do so get follow-up blood tests?~2. Were all the formal diagnostic tests performed?~3. Did the formal tests correlate to the POC HbA1c test or was there significant discrepancy? Thus is this new test for diagnosing diabetes confirmed as a valid test for screening in First Nation Communities in Canada?~4. Did the family physicians find this useful?
Study NCT01333176 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HbA1c blood test
Description: All candidates will have a HbA1c blood test (Finger poke)
Study NCT01333176 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HbA1c finger poke test
Description: All study candidates will have the same HbA1c test performed
Study NCT01333176 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood test
Description: HbA1c blood test
Study NCT01333176 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood test
Description: HbA1c finger poke blood test
Study NCT04108481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Immunotherapy
Study NCT04108481 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Yttrium-90 RadioEmbolization
Description: Microscopic radioactive particles (TheraSphere®) will be used for radioembolization to deliver the Y90 drug to the liver
Study NCT04928833 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates Training
Description: Pilates training was carried out as group exercises for about 1 hour, 3 days a week for 8 weeks. Before starting the exercise training, all subjects were taught the key elements of Pilates in 1 session. Pilates training started with standing exercises for warming up and centering in the supine position. Training continued with upper and lower extremity movements. The intensity of the exercises was increased using different positions and elastic bands. Stretching exercises and posture exercises were used during the cooling period. All exercises were started with 10 repetitions and then increased to 20. In order for the patients to perform the movements correctly, each movement was first demonstrated by the physiotherapist. The movements that the patients could not do were applied by modifying them in a suitable way.
Study NCT04928833 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Breathing exercises, active range of motion exercises and relaxation exercises were given to the control group as a home program. They were asked to do the exercises 3 days a week for 8 weeks.
Study NCT03305432 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: sleeve + preoperative PPI
Description: sleeve + preoperative PPI
Study NCT03305432 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: sleeve + preoperative Placebo
Description: sleeve + preoperative Placebo
Study NCT03951597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combined therapy using oxaliplatin and gemcitabine chemotherapy, Lenvatinib and PD1 antibody (JS001)
Description: 1. Gemox chemotherapy Day1 oxaliplatin 85mg/m2+ gemcitabine 1g/m2, Day8 gemcitabine 1g/m2 Three weeks is a course of treatment with a total of 6 courses.~2. Lenvatinib (8mg/d), continuous use for 1 year.~3. PD-1 antibody (JS001) (240mg every 3 weeks), continuous use for 1 year.
Study NCT05017376 — intervention group
Intervention type: PROCEDURE
Intervention: small incision lenticular extraction
Description: In patients with the same degree of myopia, different optical zones were designed for operation
Study NCT01045187 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: brachytherapy
Description: Electronic brachytherapy dose 21 Gy or 22 Gy in 3-4 fractions prescribed to 5mm depth, or electronic brachytherapy 16-18 Gy if EBRT is administered.
Study NCT01045187 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Xoft Axxent Electronic Brachytherapy System
Description: 21-22 Gy in 3-4 fractions to 5mm or 16-18 Gy in 3 fractions prescribed to the surface.
Study NCT01109485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olopatadine hydrochloride ophthalmic solution 0.1%
Description: 1-2 drops 4 times per day
Study NCT01038986 — intervention group
Intervention type: BIOLOGICAL
Intervention: CureXcell
Description: The CureXcell™ dosage form consists of an aseptically-processed activated cell suspension that has been isolated, activated and purified from the peripheral blood of healthy allogeneic donors, by hypo-osmotic shock, using the MacroCure custom closed bag system.
Study NCT03827681 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trans Intrahepatic Portosystemic Shunt
Description: * The most common approach is through the right internal jugular approach.~* After infiltrating the puncture site with 2% lignocaine and puncturing the vein a guide wire is advanced into the IVC followed by a 9F/10F vascular sheath.~* A wedged venogram is performed with a peripherally placed hepatic vein catheter, which may identify a portion of the portal vein to facilitate subsequent puncture.'~* A stiff guide wire is then passed through the catheter and the vascular sheath is advanced into the right hepatic vein. With the vascular sheath in place a rigid needle with 15-20 degrees of distal angulation is advanced over the guide wire and through the vascular sheath to enter the hepatic vein.
Study NCT03827681 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Self Expanding Metallic Stent
Description: * At upper endoscopy, a 0.35 Superstiff radiological guidewire with a soft tip (supplied with the stent insertion kit) is delivered into the stomach under direct vision and the endoscope is removed.~* The stent delivery device is then advanced over the guidewire into the stomach, and the distal portion of the stent delivery system is withdrawn to allow inflation of the gastric balloon.~* The gastric balloon is then inflated with 100 mL of air, and the whole delivery system is withdrawn until resistance is felt, which signifies that the balloon is impacting at the cardia, thus anchoring the distal end of the stent during deployment.~* After stent deployment, the gastric balloon is deflated and the stent delivery system is withdrawn. The stent is then examined endoscopically. When deployed, the stent is 135 mm long and 25 mm wide.
Study NCT03827681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasoactive Agent
Description: Vasoactive Agent
Study NCT03827681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasoactive Agent
Description: Vasoactive Agent
Study NCT00661557 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal vaccine GSK134612 (Nimenrix)
Description: one dose, as intramuscular injection